• Proceedings of the Korean Society of Toxicology Conference
• /
• 2002.05a
• /
• pp.114-114
• /
• 2002

Inhibitors of type IV phosphodiesterase (PDE IV) are currently being developed as new therapeutic agents for asthma, chronic obstructive pulmonary disease(COPD) and arthritis. Unfortunately, the anti-inflammatory effect of PDE IV inhibitors has been considered to be associated to some extent with vomiting as adverse effect. The first generation PDE IV inhibitor, rolipram, was known to induce emesis at clinical trials. (omitted)

• Proceedings of the Korean Society of Applied Pharmacology
• /
• 2000.04a
• /
• pp.8-9
• /
• 2000

Despite the advances made in the past few decades in cancer chemotherapy, many conventional anticancer drugs display relatively poor selectivity for cancer cells. The nonselectivity of anticancer drugs and the development of anticancer drug resistance have been recognized as serious limitations in their clinical usefulness. Therefore, a major challenge in cancer chemotherapy is the development of new anticancer agents with improved selectivity for tumor cells as well as the prevention of the host cell resistance, both of which result in the improvement of therapeutic effect against cancer cells. Cyclophosphamide (CP), a widely used anticancer agent, is a prodrug that is activated by hepatic microsomal mixed-function oxidase (MFO) catalyzed C$_4$- hydroxylation. The resulting 4-hydroxycyclophosphamide (4-OH-CP) is converted to the ring-opened tautomer to aldophosphamide (Aldo) which subsequently undergoes a base- catalyzed ${\beta}$-elimination to generate cytotoxic phosphoramide mustard (PDA) and acrolein. The cytotoxic activity of CP is attributed to the aziridinium ion species derived from PDA that cross-links interstrand DNA.

• Pediatric Gastroenterology, Hepatology & Nutrition
• /
• v.15 no.1
• /
• pp.1-7
• /
• 2012

Noroviruses (NoVs) are one major etiologic agent in acute gastroenteritis (AGE) in all ages and are the primary cause of food-borne gastroenteritis worldwide. GII-4 NoVs has predominated since 1990s, and novel recombinant strains have been reported worldwide. Researchers face difficulties in making vaccines and therapeutic agents against NoVs due to the lack of cell culture and animal-model systems and the rapid emergence of novel variant strains. Recently, a randomized clinical trial for intranasal NoVs vaccine has been reported, which casts a light in the way of vaccine production. This review discusses the recent findings on the structure, immunity, and vaccination of NoVs.

• Environmental Mutagens and Carcinogens
• /
• v.25 no.3
• /
• pp.87-96
• /
• 2005

[ $p16^{INK4a}$ ] is a tumor suppressor that belongs to the INK4 family of the cyclin D-dependent kinases (cdk) inhibitors. It plays regulatory roles in cell proliferation and in tumorigenesis by interacting with Rb signaling. Abnormally elevated $p16^{INK4a}$ protein expression causes cell cycle arrest (G1/S transition) and loss of cyclin-cdk activity. In many cancers, $p16^{INK4a}$ is altered by mutation, deletion, and promoter methylation. This review summarizes the function of p16 as an important regulator of cancer pathobiology and a promising target fer developing cancer therapeutic and chemopreventive agents.

• Asian Pacific Journal of Cancer Prevention
• /
• v.15 no.2
• /
• pp.585-588
• /
• 2014

Colorectal cancer is one of the most prevalent diseases all over the world. Early screening and start of chemotherapy is effective in decreasing mortality. This type of cancer can be controlled to some extent via a healthy diet rich in fruit and vegetables. Ginseng is a plant which has been consumed as a herbal medicine for thousands of years in Asian countries. Several in vitro and in vivo studies have shown that this plant not only reduces the incidence of colorectal cancer, but also improves patient's status by enhancing the effects of chemotherapy drugs. However, further studies are needed to prove this relationship. We briefly review ginseng and its components such as ginsenosides reported anticancer effects and their mechanisms of action. Understanding these relationships may produce insights into chemical and pharmacological approaches for enhancing the chemo preventive effects of ginsenosides and for developing novel anticancer agents.

• Fisheries and Aquatic Sciences
• /
• v.19 no.9
• /
• pp.37.1-37.5
• /
• 2016

Human immunodeficiency virus (HIV) is the causative agent of acquired immune deficiency syndrome (AIDS). Anti-HIV agents targeting various steps in HIV life cycle have been developed; however, so far, no effective drugs have been found. We show here that a peptide isolated from Spirulina maxima (SM-peptide) inhibits HIV-1 infection in a human T cell line MT4. SM-peptide inhibited $HIV-1_{IIIB}$-induced cell lysis with a half-maximal inhibitory concentration ($IC_{50}$) of 0.691 mM, while its 50 % cytotoxic concentration ($CC_{50}$) was greater than 1.457 mM. Furthermore, the SM-peptide inhibited the HIV-1 reverse transcriptase activity and p24 antigen production. This suggests that SM-peptide is a novel candidate peptide, which may be developed as a therapeutic agent for acquired immunodeficiency syndrome patients.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• v.34 no.2
• /
• pp.200-206
• /
• 2008

A variety of mechanisms may generate pain resulting from injury to the peripheral nervous system. None of these mechanisms is disease-specific, and several different pain mechanisms may be present simultaneously in any one patient. Diagnosis of neuropathic pain is often easily made from the information gathered on neurologic examination and from patient history. Evidence of sensory disturbances elicited by examination combined with laboratory tests confirming injury to peripheral nerve establishes the diagnosis of neuropathic pain. Although treatment of neuropathic pain may be difficult, optimum treatment can be achieved if dentist has a complete understanding of the therapeutic options. Pharmacologic therapy has been the mainstay of treatment. Selection of an appropriate pharmacologic agent is by trial and error since individual response to different agents, doses, and serum level are highly variable. An adequate trial for each agent tried is key to pharmacologic treatment of neuripathic pain. If pharmacologic treatment is not effective, nerve block using lidocaine, steroid and alcohol and neurectomy must be considered for treatment option.

• Journal of Pharmaceutical Investigation
• /
• v.22 no.1
• /
• pp.1-10
• /
• 1992

The use of erythrocyte as drug carrier has been reviewed, Carrier erythrocytes have proven to offer many advantages for delivery of therapeutic agents, especially in the treatment of inherited enzyme deficiency and cancer. Carrier erythrocytes are biodegradable and nonimmunogenic. Encapsulated drugs may be protected from premature degradation, inactivation and excretion. Carrier erythrocytes may be used as a slow-release system. Targeting of encapsulated drugs directly to a site of action is another possibility. Methods for encapsulating drugs into erythrocytes, the fate of carrier erythrocytes in vivo, the strategies of targeting carrier erythrocytes to special organs and in vivo applications of erythrocytes have been discussed. The encapsulation of drugs in erythrocytes has shown attractive possibilites in future use.

• Journal of Dairy Science and Biotechnology
• /
• v.30 no.2
• /
• pp.139-143
• /
• 2012

For human including newborn baby, the intestinal microbiota can play an important role in the development of the intestinal mucosa and in maintaining the balance of the immune cells. Important functions of the intestinal microbiota include the inhibition of the colonization of the intestine by potentially pathogenic microorganisms. Thus, the research of probiotics have been focused on the prevention and treatment of disorders associated with the gastrointestinal tract (GIT), including pathogen infection, traveler's diarrhea, antibiotic-associated diarrhea, and constipation. Probiotics have also been suggested as therapeutic agents against irritable bowel syndrome and inflammatory bowel diseases. An increasing amount of evidence from clinical studies suggests that they are effective in the prevention of atopic allergies and may have potential anti-carcinogenic effects. Until recent years many scientific research for this use has been based on empirical observations. Therefore, probiotics in the form of fermented milk products have been long part of attempts to maintain good health in world wide.

• Journal of Microbiology and Biotechnology
• /
• v.14 no.4
• /
• pp.680-685
• /
• 2004

The capability of lactic acid bacteria (LABs) to adhere to intestinal epithelial cells and vaginal epithelial cells is an important factor in the formation of a barrier to prevent the colonization of pathogenic bacteria. In addition, the ability to coaggregate with pathogens and production of antimicrobial agents also allow LABs to fight against pathogens. In this work, Weissella confusa PL9001 was tested for its ability to inhibit the growth and adherence of genitourinary pathogens, including Candida albicans, Escherichia coli, Staphylococcus aureus, and vancomycin-resistant Enterococcus faecium (VRE), isolated from the urine of hospitalized female patients. W. confusa PL9001 was found to coaggregate with the four pathogens, as observed with a light microscope and scanning electron microscope. In competition, exclusion, and displacement tests, the adherence of the pathogens to T24 bladder epithelial cells was also inhibited by W. confusa PL9001. Accordingly, these results suggest that W. confusa PL9001 is potentially useful for both preventive and therapeutic treatment of genitourinary infections.